1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
A novel series of 1-sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists was discovered through high throughput screening (HTS) and medicinal chemistry lead optimization. Potency and in vivo properties were systematically optimized to afford orally bioavailable, highly efficacious, and selective CB1R inverse agonists that caused food intake suppression and body weight reduction in diet-induced obese rats and dogs. It was found that the receptor binding assay predicted in vivo efficacy better than functional antagonist/inverse agonist activities. This observation expedited the structure-activity relationship (SAR) analysis and may have implications beyond the series of compounds presented herein.
Vachal
Petr
P
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065, USA. petr_vachal@merck.com
Fletcher
Joan M
JM
Fong
Tung M
TM
Huang
Cathy C R-R
CC
Lao
Julie
J
Xiao
Jing C
JC
Shen
Chun-Pyn
CP
Strack
Alison M
AM
Shearman
Lauren
L
Stribling
Sloan
S
Chen
Richard Z
RZ
Frassetto
Andrea
A
Tong
Xinchun
X
Wang
Junying
J
Ball
Richard G
RG
Tsou
Nancy N
NN
Hickey
Gerard J
GJ
Thompson
Donald F
DF
Faidley
Terry D
TD
Nicolich
Susan
S
Achanfuo-Yeboah
Joana
J
Hora
Donald F
DF
Hale
Jeffrey J
JJ
Hagmann
William K
WK